Teacher Retirement System of Texas Acquires New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)

Teacher Retirement System of Texas bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) during the 4th quarter, HoldingsChannel reports. The firm bought 10,753 shares of the company’s stock, valued at approximately $276,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. FMR LLC lifted its position in shares of NewAmsterdam Pharma by 35.6% in the 3rd quarter. FMR LLC now owns 330,412 shares of the company’s stock worth $5,485,000 after purchasing an additional 86,712 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in NewAmsterdam Pharma by 1,231.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after buying an additional 221,305 shares in the last quarter. Walleye Capital LLC purchased a new stake in NewAmsterdam Pharma during the third quarter worth $779,000. ArrowMark Colorado Holdings LLC boosted its position in NewAmsterdam Pharma by 19.5% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 354,975 shares of the company’s stock valued at $5,893,000 after acquiring an additional 57,806 shares in the last quarter. Finally, Cinctive Capital Management LP boosted its position in NewAmsterdam Pharma by 77.7% during the 3rd quarter. Cinctive Capital Management LP now owns 66,571 shares of the company’s stock valued at $1,105,000 after acquiring an additional 29,115 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, Director James N. Topper bought 4,005 shares of the company’s stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average cost of $21.02 per share, for a total transaction of $84,185.10. Following the transaction, the director now directly owns 3,012,434 shares of the company’s stock, valued at approximately $63,321,362.68. The trade was a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at approximately $305,550. This represents a 90.91 % decrease in their position. The disclosure for this sale can be found here. 19.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on NAMS. Needham & Company LLC reduced their price target on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $48.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Royal Bank of Canada restated an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Scotiabank raised their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $43.33.

NewAmsterdam Pharma Stock Down 10.2 %

NAMS opened at $18.38 on Wednesday. The firm’s 50-day moving average price is $21.50 and its 200-day moving average price is $21.32. The company has a market cap of $2.02 billion, a P/E ratio of -7.07 and a beta of -0.04. NewAmsterdam Pharma has a 52-week low of $15.19 and a 52-week high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $3.30 million. On average, research analysts anticipate that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.